Bolt Biotherapeutics Stock
Bolt Therapeutics plans to develop a novel format for T-cell mediated anti-tumour therapy.
About Bolt Biotherapeutics Stock
Bolt Therapeutics plans to develop a novel format for T-cell mediated anti-tumour therapy.
Funding History
| March 2015 | $600K |
|---|---|
| September 2016 | $10.0M |
| August 2018 | $19.4M |
| February 2019 | $54.0M |
Management
President and CEO
Reiner Laus
Chief Business Officer
Grant Yonehiro
Chief Executive Officer and Director
CP Liu
Founder
Edgar Engleman
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Bolt Biotherapeutics or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
